Roivant Sciences (ROIV) Earnings Date & Reports

Key Takeaways

• Roivant reported Q4 revenue of $2.52 million and full-year revenue of $8.26 million for the period ended March 31, 2026.
• The company posted net income from continuing operations of $355.7 million in Q4, driven largely by a $770.2 million litigation settlement gain.
• Diluted EPS came in at $0.28 for Q4 and a $0.54 loss for the full fiscal year.
• Consolidated cash, cash equivalents, and marketable securities stood at $4.3 billion at fiscal year-end.
• Key clinical updates highlighted progress in IMVT-1402 for difficult-to-treat rheumatoid arthritis and brepocitinib programs.
• Management emphasized a cash runway extending into profitability supported by the strong balance sheet.

Earnings Context and Why It Matters

Roivant Sciences operates in the biopharmaceutical sector, focusing on developing and commercializing therapies through its subsidiaries. The fourth quarter and fiscal year ended March 31, 2026, represent a pivotal reporting period as the company advances multiple late-stage assets. Investors closely monitor these results for insights into operational efficiency, R&D spending trends, and the ability to extend its cash position amid ongoing clinical development. This report also provides visibility into upcoming regulatory milestones that could influence the company’s trajectory over the next 12 to 18 months.

Reported Results

Roivant reported revenue of $2.52 million for the fourth quarter and $8.26 million for the full fiscal year ended March 31, 2026. Net income from continuing operations reached $355.7 million in the quarter, compared with a $252.4 million loss in the prior-year period, primarily due to a $770.2 million gain on litigation settlement. For the full year, the company recorded a net loss from continuing operations of $397.9 million. Diluted earnings per share totaled $0.28 for the quarter and a $0.54 loss for the fiscal year. Research and development expenses rose to $198.9 million in the quarter and $681.8 million for the year. General and administrative expenses increased modestly year over year. The company ended the period with $4.3 billion in cash, cash equivalents, and marketable securities.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Market Reaction and Investor Sentiment

Following the May 20, 2026, earnings release, investor attention centered on the substantial litigation settlement gain and the company’s robust cash position. Market participants appeared focused on the implications for ongoing clinical programs rather than quarterly revenue figures, which remained modest as expected for a development-stage biopharmaceutical firm. Positive commentary around pipeline updates helped shape sentiment heading into the post-earnings period.

Forward Outlook and Key Factors to Monitor

Investors should watch for updates on Roivant’s key development programs in the second half of calendar 2026. Brepocitinib is set for a potential commercial launch in dermatomyositis by the end of September 2026, following FDA acceptance of the new drug application with priority review. Additional Phase 3 data readouts are expected for brepocitinib in non-infectious uveitis and cutaneous sarcoidosis. For IMVT-1402, topline results from studies in difficult-to-treat rheumatoid arthritis and cutaneous lupus erythematosus are anticipated later this year. Enrollment completion and data from the mosliciguat Phase 2 trial in pulmonary hypertension associated with interstitial lung disease will also provide important visibility.

Further monitoring of the company’s cash deployment will be essential, as the $4.3 billion balance sheet supports continued investment in late-stage trials. Regulatory decisions, including any additional breakthrough therapy designations or NDA acceptances, could serve as near-term catalysts. Clinical execution across these programs will remain a primary focus for assessing progress toward potential commercialization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations